Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Descemet Stripping Endothelial Keratoplasty | 14 | 2022 | 19 | 6.360 |
Why?
|
| Endothelium, Corneal | 9 | 2022 | 19 | 3.550 |
Why?
|
| Corneal Diseases | 6 | 2022 | 32 | 3.430 |
Why?
|
| Fuchs' Endothelial Dystrophy | 6 | 2017 | 11 | 2.160 |
Why?
|
| Descemet Membrane | 5 | 2022 | 5 | 1.740 |
Why?
|
| Tissue and Organ Harvesting | 5 | 2022 | 78 | 1.030 |
Why?
|
| Corneal Endothelial Cell Loss | 7 | 2022 | 7 | 0.870 |
Why?
|
| Graft Rejection | 3 | 2017 | 1065 | 0.840 |
Why?
|
| Cornea | 2 | 2019 | 69 | 0.700 |
Why?
|
| Cell Count | 6 | 2022 | 195 | 0.680 |
Why?
|
| Fiducial Markers | 1 | 2017 | 7 | 0.610 |
Why?
|
| Visual Acuity | 5 | 2019 | 194 | 0.590 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2016 | 14 | 0.590 |
Why?
|
| Medical Errors | 1 | 2017 | 115 | 0.560 |
Why?
|
| Postoperative Care | 1 | 2016 | 221 | 0.530 |
Why?
|
| Graft Survival | 2 | 2015 | 884 | 0.520 |
Why?
|
| Sulfur Hexafluoride | 3 | 2017 | 4 | 0.440 |
Why?
|
| Anterior Eye Segment | 1 | 2012 | 6 | 0.440 |
Why?
|
| Iris | 1 | 2012 | 5 | 0.440 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2012 | 4 | 0.440 |
Why?
|
| Uveitis | 1 | 2012 | 29 | 0.420 |
Why?
|
| Cosmetic Techniques | 1 | 2012 | 28 | 0.420 |
Why?
|
| Tissue Donors | 4 | 2022 | 463 | 0.420 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 121 | 0.410 |
Why?
|
| Blepharitis | 1 | 2011 | 2 | 0.400 |
Why?
|
| Azithromycin | 1 | 2011 | 13 | 0.390 |
Why?
|
| Dry Eye Syndromes | 1 | 2011 | 5 | 0.390 |
Why?
|
| Eye Infections, Bacterial | 1 | 2011 | 14 | 0.390 |
Why?
|
| Acanthamoeba Keratitis | 2 | 2021 | 8 | 0.380 |
Why?
|
| Corneal Pachymetry | 2 | 2017 | 2 | 0.300 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2016 | 23 | 0.270 |
Why?
|
| Phacoemulsification | 2 | 2016 | 16 | 0.270 |
Why?
|
| Humans | 20 | 2022 | 86643 | 0.260 |
Why?
|
| Acanthamoeba | 2 | 2021 | 17 | 0.240 |
Why?
|
| Phosphorylcholine | 2 | 2021 | 28 | 0.230 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 49 | 0.210 |
Why?
|
| Eye Infections, Parasitic | 1 | 2019 | 4 | 0.180 |
Why?
|
| Endotamponade | 2 | 2016 | 4 | 0.180 |
Why?
|
| Iatrogenic Disease | 2 | 2017 | 69 | 0.180 |
Why?
|
| Microscopy, Confocal | 2 | 2019 | 268 | 0.180 |
Why?
|
| Reoperation | 2 | 2017 | 597 | 0.160 |
Why?
|
| Corneal Edema | 1 | 2017 | 6 | 0.160 |
Why?
|
| Intraoperative Complications | 2 | 2015 | 185 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2017 | 8489 | 0.150 |
Why?
|
| Air | 1 | 2016 | 62 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2022 | 1578 | 0.140 |
Why?
|
| Cataract | 1 | 2016 | 86 | 0.140 |
Why?
|
| Tissue Transplantation | 1 | 2015 | 12 | 0.140 |
Why?
|
| Operative Time | 1 | 2016 | 127 | 0.140 |
Why?
|
| Regeneration | 1 | 2016 | 143 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 175 | 0.130 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 130 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2017 | 7993 | 0.120 |
Why?
|
| Blast Injuries | 1 | 2014 | 11 | 0.120 |
Why?
|
| Mass Casualty Incidents | 1 | 2014 | 12 | 0.120 |
Why?
|
| Eye Injuries | 1 | 2014 | 15 | 0.120 |
Why?
|
| Pseudophakia | 1 | 2013 | 3 | 0.120 |
Why?
|
| Refraction, Ocular | 1 | 2013 | 9 | 0.120 |
Why?
|
| Female | 9 | 2019 | 44532 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 429 | 0.120 |
Why?
|
| Aged | 5 | 2017 | 18415 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6509 | 0.110 |
Why?
|
| Silicone Elastomers | 1 | 2012 | 7 | 0.110 |
Why?
|
| Male | 8 | 2019 | 40965 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 209 | 0.100 |
Why?
|
| Ophthalmic Solutions | 1 | 2011 | 16 | 0.100 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2011 | 16 | 0.100 |
Why?
|
| Device Removal | 1 | 2012 | 161 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3640 | 0.080 |
Why?
|
| Middle Aged | 5 | 2022 | 25028 | 0.080 |
Why?
|
| Adult | 6 | 2019 | 25648 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1961 | 0.070 |
Why?
|
| Time Factors | 1 | 2015 | 5210 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1565 | 0.070 |
Why?
|
| Eye Banks | 2 | 2015 | 3 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 746 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1036 | 0.060 |
Why?
|
| Slit Lamp Microscopy | 1 | 2019 | 5 | 0.050 |
Why?
|
| DNA, Protozoan | 1 | 2019 | 16 | 0.050 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 33 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2019 | 684 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 285 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2016 | 90 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2207 | 0.030 |
Why?
|
| Gentian Violet | 1 | 2015 | 10 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2015 | 64 | 0.030 |
Why?
|
| Bombs | 1 | 2014 | 1 | 0.030 |
Why?
|
| Explosive Agents | 1 | 2014 | 4 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 33 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 101 | 0.030 |
Why?
|
| Lenses, Intraocular | 1 | 2013 | 12 | 0.030 |
Why?
|
| Benchmarking | 1 | 2013 | 78 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 115 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2013 | 303 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1621 | 0.020 |
Why?
|
| Child | 1 | 2014 | 6927 | 0.010 |
Why?
|